Introduction
============

Tacrolimus is one of the most common and potent immunosuppressive drugs used to lower the risk of acute organ rejection in patients through the suppression of the cytotoxic activity of the T lymphocytes involved in acute rejection; however, it has a narrow therapeutic window ([@B17]; [@B13]; [@B30]). The post-operation blood concentration of tacrolimus should be strictly monitored in accordance with the recommended time-dependent target trough concentrations, as subtherapeutic doses of tacrolimus are associated with acute rejection and graft loss ([@B25]) and overdosing of tacrolimus produces adverse side effects, such as nephrotoxicity and new-onset diabetes ([@B14]; [@B27]; [@B16]). The metabolism of tacrolimus, which plays an essential role in its blood concentration, is largely dependent on the cytochrome P450 3A (CYP3A) subfamily, especially CYP3A5 ([@B22]). As the genetic polymorphisms of CYP3A5 affect its expression and activity, the effects of CYP3A5 polymorphisms on the metabolism of tacrolimus have been studied thoroughly over the last few decades to provide an understanding of the variance in tacrolimus blood concentrations among patients ([@B1]; [@B8]). Patients with the CYP3A5^∗^3/^∗^3 genotype (non-expressors) receiving orthotopic liver transplantation (OLT) or renal transplantation require a lower tacrolimus dose to reach similar trough levels compared with those with the CYP3A5^∗^1 allele (expressors) ([@B19]; [@B26]; [@B2]; [@B12]). In addition to CYP3A5, single nucleotide polymorphisms (SNPs) of other genotypes have been implicated in tacrolimus metabolism, including CYP3A4 and recipient ABCB1 (adenosine triphosphate-binding cassette sub-family B member 1) ([@B27]; [@B8]; [@B6]), although no consensus has been reached. In the present study, considering that multiple unknown genes may be involved in tacrolimus metabolism, we performed a genome-wide association study (GWAS) to evaluate more than 240,000 exonic variants in 115 donors and 115 matched recipients with the associated tacrolimus trough concentrations using an exome chip, and established valid models to account for the variation in tacrolimus concentrations.

Materials and Methods {#s1}
=====================

Study Subjects
--------------

In this study, 115 donors and 115 matched recipients receiving an OLT between July 2015 and March 2017 at the First People's Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, and registered in the China Liver Transplant Registry (CLTR) database, were enrolled. All donors were from donation after brain death. This study was registered in [ClinicalTrials.gov](http://clinicaltrials.gov) and the identification number is NCT02752529. All recipients followed the same post-operation treatment protocol: oral tacrolimus, 0.1 mg/kg/day; steroids, 0.8--1.0 mg/kg/day; mycophenolate, 1.5 g/day; and lamivudine combined with low-dose intramuscular hepatitis B immunoglobulin therapy for anti-viral treatment in recipients with hepatitis B virus-related liver disease. If patients had an acute rejection reaction or renal function insufficiency, we increased or decreased the dose of anti-rejection drugs, as appropriate. The enrollment criteria were: (i) adult patients (≥18 years of age), (ii) patients that received a tacrolimus-based immunosuppressive regime. The exclusion criteria were: (i) multiorgan transplant patients; (ii) follow-up time less than 1 month; (iii) incomplete patient data. All recipients had associated follow-up information, including tacrolimus trough concentrations. Patients with pre-operative abnormal renal function were excluded. Informed consent was obtained from all subjects or their direct relatives. The study was approved by the Institutional Review Board and conducted strictly in accordance with the guidelines of the Ethics Committee of the Shanghai First Hospital affiliated with Shanghai Jiao Tong University. The methods were conducted in accordance with the Declaration of Helsinki and its later amendments.

Data Collection
---------------

The individual medical records of each enrolled subject were reviewed and recorded at the time of inclusion in the study. The age, gender, body mass index (BMI), blood type, and HLA mismatch of all included subjects were collected. The clinical laboratory index of recipients before and after operation, including glutamic-pyruvic transaminase (ALT), total bilirubin (TB), creatinine (Cr), hemoglobin (Hb), and direct bilirubin (DB), was measured uniformly in the clinical laboratory of the Shanghai General Hospital, affiliated to Shanghai Jiao Tong University. Tacrolimus trough concentrations were measured before morning administration in the first 4 weeks post-operation. Natural logarithms of tacrolimus dose-normalized tacrolimus trough concentration \[ln (TAC C~0~/D ratio)\] (nanograms per milliliter per total daily dose in milligrams, ng/mL/mg) were calculated before applying statistical analysis.

Genotyping and Genome-Wide Association Study (GWAS)
---------------------------------------------------

Liver tissue (20--50 mg) was extracted from each donor and recipient, and tacrolimus trough concentration was measured in the whole blood by using the Pro-TracTMII tacrolimus ELISA kit (Diasorin, Stillwater, MN, United States) with a microparticle enzyme immunoassay (ELx 800NB analyzer, BioTek, Winooski, VT, United States). The genomic DNA was collected by using the AllPrep DNA Mini Kit (QIAGEN, Hilden, Germany). DNA concentration was quantified by using a NanoDrop ND2000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, United States). All DNA samples were amplified in two separate multiplex PCR assays. PCR products were cleaned up using AMPure XP Beads (Beckman Coulter, Pasadena, CA, United States) ([@B15]). Genotypes of all samples were determined by Infinium Human Exome-12 v1.2 BeasChip accessing \> 240,000 exonic variants. The CYP3A5 genotype was selected from the Drug Metabolizing Enzymes and Transporters (DMET) chip ([@B18]).

Statistical Analysis
--------------------

Quantitative variables were expressed as the mean ± standard deviation (SD) or the median and interquartile range (IQR). Categorical variables were presented as values and compared by using Pearson's χ^2^ test. The minor allele frequency (MAF) was set as 0.1. The Hardy--Weinberg Equilibrium (HWE) test was performed using an appropriate χ^2^ test. Pairwise *R*^2^ and *D*-values for linkage disequilibrium were calculated by using SHEsis software^[1](#fn01){ref-type="fn"}^. SNPs of raw *P*-value with significance were then analyzed according to intersections between 4 weeks of post-operation data collected separately from donors and recipients. SNPs in these intersections were further verified through univariate and multivariate regression analysis, together with clinical baseline characteristics. The significant variables, as determined by multivariate regression analysis, were used to establish a model that could account for the ln(TAC C~0~/D ratio) observed in the convalescence period (CP) and the stabilizing period (SP). Genotype data analysis and quality control were performed by using PLINK software ([@B24])^[2](#fn02){ref-type="fn"}^. SPSS version 22.0 (SPSS Inc., Chicago, IL, United States) and GraphPad Prism 7 (GraphPad Prism Software Inc., San Diego, CA, United States) were used to perform statistical analysis. Manhattan plots and Venn diagrams were generated by using R Studio^[3](#fn03){ref-type="fn"}^. A two-tailed *P*-value of \< 0.05 was deemed significant.

Results
=======

Baseline Characteristics
------------------------

In the study, 115 donors (114 male and 1 female) and 115 recipients (96 male and 19 female) were enrolled in the study. The ages and BMI of donors were not available. There was no significant difference in gender between donors and recipients (*P* = 1.0). The MELD (model for end stage of liver disease) score of recipients was 11.4 ± 5.9. The clinical laboratory indices of recipients pre- and post-operation are detailed in [Table 1](#T1){ref-type="table"}. The median value of dose-normalized tacrolimus trough concentrations was 5.3 ng/mL/mg (IQR: 4.8--5.8 ng/mL/mg) in Weeks 1--2, and 4.7 ng/mL/mg (IQR: 4.3--5.3 ng/mL/mg) in Weeks 3--4.

###### 

Characteristic of patients.

                                                                                       Recipient (*n* = 115)
  ------------------------------------------------------------------------------------ -----------------------
  Age, years (mean ± SD)                                                               47.3 ± 9.0
  Gender, male/female, n                                                               96/19
  BMI, kg/m2, (mean ± SD)                                                              23.1 ± 5.0
  MELD score (mean ± SD)                                                               11.4 ± 5.9
  ALT.pre, U/l, median (IQR)                                                           18.0 (12.0--39.0)
  TB.pre, μmol/L, median (IQR)                                                         23.0 (13.0--48.0)
  Cr.pre, mg/dl, median (IQR)                                                          60.0 (47.0--70.0)
  Hb.pre, g/L, median (IQR)                                                            107.0 (81.0--134.0)
  ALT.post, U/l, median (IQR)                                                          86.6 (62.8--131.8)
  TB.post, μmol/L, median (IQR)                                                        36.5 (21.7--63.0)
  Cr.post, μmol/L, median (IQR)                                                        57.4 (51.3--74.8)
  Hb.post, g/L, median (IQR)                                                           97.9 (89.3--107.7)
  Tacrolimus dose normalized tacrolimus trough in weeks 1--2, ng/mL/mg, median (IQR)   5.3 (4.8--5.8)
  Tacrolimus dose normalized tacrolimus trough in weeks 3--4, ng/mL/mg, median (IQR)   4.7 (4.3--5.3)

\#, missing; BMI, body mass index; ALT.pre, glutamic-pyruvic transaminase detected before transplant; TB.pre, total bilirubin detected before transplant; Cr.pre, creatinine detected before transplant; Hb.pre, hemoglobin detected before transplant; ALT.post, glutamic-pyruvic transaminase detected after transplant; TB.post, total bilirubin detected after transplant; Cr.post, creatinine detected after transplant; Hb.post, hemoglobin detected after transplant; IQR, interquartile range.

Genome-Wide Association Study
-----------------------------

GWAS was performed using \> 240,000 markers on the 115 patient pairs (115 donors and 115 recipients), evaluating the association between SNPs and the natural log of tacrolimus concentration/dose ratios between donors and recipients in the first 4 weeks after OLT, adjusted for age, donor gender, recipient gender, and BMI. All SNPs were shown in order from chromosome 1 to 23 (excluding the Y chromosome). P-values were calculated for all SNPs and were shown in a Manhattan plot ([Figure 1](#F1){ref-type="fig"}). The total number of significant correlative SNPs in donors was 105 in Week 1, 103 in Week 2, 123 in Week 3, and 113 in Week 4; in recipients, the number was 138 in Week 1, 132 in Week 2, 138 in Week 3, and 117 in Week 4 ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}).

![Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in donors and recipients respectively. Total \> 240,000 markers were analyzed toward natural log of dose-normalized tacrolimus trough concentrations between donors and recipients in the first 4 weeks with adjustment of age, donor gender, gender and BMI. All SNPs were shown in order from chromosome 1 to 23 (not including Y chromosome). **(A)** Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in donors in week 1. **(B)** Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in donors in week 2. **(C)** Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in donors in week 3. **(D)** Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in donors in week 4. **(E)** Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in recipients in week 1. **(F)** Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in recipients in week 2. **(G)** Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in recipients in week 3. **(H)** Manhattan plots of single-nucleotide polymorphisms (SNPs) associated with ln(TAC C~0~/D ratio) in recipients in week 4.](fgene-10-00528-g001){#F1}

Analysis of Differences in Liver Function in Convalescence and Stabilizing Periods
----------------------------------------------------------------------------------

The liver function of recipients was followed up over the first 4 weeks post-operation as represented by four indicators: alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin (DB), and total bilirubin (TB). All four indicators were higher in the first 2 weeks (the convalescence period of liver function; CP) than in the latter 2 weeks (the stabilizing period of liver function; SP). Significant differences between the two phases were observed in ALT (*P* = 0.011), DB (*P* \< 0.0001), and TB (P \< 0.0001) levels, and the difference in AST almost reached statistical significance (*P* = 0.078) ([Figure 2](#F2){ref-type="fig"}).

![Differences of convalescence phase and stabilizing phase of liver function. ALT, glutamic-pyruvic transaminase; AST, glutamic oxalacetic transaminase; TB, total bilirubin; DB, direct bilirubin. *P* \< 0.05 was considered significant.](fgene-10-00528-g002){#F2}

Correlative SNPs Between CP and SP in Donors and Recipients
-----------------------------------------------------------

A Venn diagram of the correlative SNPs with statistical significance in the GWAS of the CP and SP is shown in [Figure 3](#F3){ref-type="fig"}. The number of intersections in donors was 5 in the CP (intersection between the red and blue ellipses) and 10 in the SP (intersection between the green and yellow). In recipients, the numbers of intersections in the CP and SP were 4 and 6, respectively. Specific genotypes are detailed in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}.

###### 

Univariate and multivariate regression analysis in convalescence phase.

              Univariate   Multivariate                                                                                           
  ----------- ------------ -------------- ---- ---------- -------- ----------- -------- ----------- -------- ----------- -------- -----------
  Donor       rs776746     CYP3A5         7    99672916   0.286    **0.008**   0.286    **0.008**   0.194    0.058       47.733   0.062
  Donor       rs12677741   PXDNL          8    52529097   −0.011   0.909       −0.011   0.904                                     
  Donor       rs1058029    TMX4           20   7961715    −0.208   0.412       −0.208   0.464                                     
  Donor       rs1927321                   9    1.21E+08   0.310    **0.001**   0.310    **0.007**   0.233    **0.008**   0.233    **0.015**
  Donor       rs1827293    NBPF3          1    21795388   −0.158   0.078       −0.158   0.073                                     
  Donor       rs1057192    FAM26F         6    1.17E+08   −0.345   **0.000**   −0.345   **0.001**   −0.289   **0.001**   −0.289   **0.001**
  Recipient   rs11605576   SLC22A20       11   64981522   0.013    0.912       0.013    0.922                                     
  Recipient   rs11605632   SLC22A20       11   64981587   0.013    0.912       0.013    0.931                                     
  Recipient   rs12420456   SLC22A20       11   64981837   0.013    0.912       0.013    0.923                                     
  Recipient   rs3826736    C19orf45       19   7571030    0.263    **0.012**   0.263    **0.019**   0.162    0.101       0.162    0.067
  Recipient   rs776746     CYP3A5         7    99672916   0.312    **0.004**   0.312    **0.017**   0.204    0.044       0.204    0.090
  Recipient   Age                                         0.000    0.968       0.000    0.979                                     
  Recipient   Gender                                      −0.069   0.704       −0.069   0.673                                     
  Donor       Gender                                      −0.040   0.956       −0.040   0.615                                     
  Recipient   BMI                                         0.027    0.295       0.027    0.295                                     
  Recipient   MELD score                                  0.011    0.323       0.011    0.277                                     
  Recipient   ALT.pre                                     0.002    0.084       0.002    **0.030**   0.000    0.773       0.000    0.732
  Recipient   TB.pre                                      0.001    0.125       0.001    0.278                                     
  Recipient   Cr.pre                                      0.004    0.069       0.004    **0.045**   0.004    **0.022**   0.004    **0.026**
  Recipient   Hb.pre                                      0.001    0.707       0.001    0.663                                     

BMI, body mass index; ALT.pre, glutamic-pyruvic transaminase detected before transplant; TB.pre, total bilirubin detected before transplant; Cr.pre, creatinine detected before transplant; Hb.pre, hemoglobin detected before transplant. Bold values indicate the significant level at P \< 0.05.

![Venn diagram showed the correlation between week1 and week2 (convalescence phase), as well as week3 and week4(stabilizing phase) in donors and recipients respectively. The numbers meant the number of intersections between or among weeks. 0 meant no intersection.](fgene-10-00528-g003){#F3}

###### 

Univariate and multivariate regression analysis in stabilizing phase.

              Univariate   Multivariate                                                                                                
  ----------- ------------ -------------- ---- ----------- ---------- ----------- ---------- ----------- -------- ----------- -------- -----------
  Donor       rs776746     CYP3A5         7    99672916    0.349      **0.001**   0.349      **0.001**   0.308    **0.000**   0.336    **0.014**
  Donor       rs6678469    KAZN           1    14281451    0.237      **0.008**   0.237      **0.006**   0.045    0.540       0.043    0.558
  Donor       rs2667662    TELO2          16   1551082     0.282      **0.002**   0.282      **0.001**   0.221    **0.003**   0.218    **0.014**
  Donor       rs7980521    ESYT1          12   56535251    −0.295     **0.002**   −0.295     **0.005**   −0.283   **0.000**   −0.283   **0.014**
  Donor       rs4401444    LOC101928987   4    82620131    −0.209     **0.046**   −0.209     **0.048**   −0.099   0.162       −0.099   0.156
  Donor       rs4903096    --             14   40329432    −0.318     **0.001**   −0.318     **0.001**   −0.269   **0.000**   −0.269   **0.007**
  Donor       rs8916       EIF4B          12   53433486    0.431      **0.000**   0.431      **0.002**   0.113    0.142       0.113    0.156
  Donor       rs6719889    LOC101927261   2    58237076    −0.141     0.230       −0.141     0.102                                     
  Donor       rs2302310    QRFPR          4    122250734   −0.002     0.988       −0.002     0.988                                     
  Donor       rs9778       ESD            13   47354101    −0.164     0.078       −0.164     0.085                                     
  Donor       rs2276231    LOC105372795   21   38437951    0.091      0.706       0.091      0.661                                     
  Recipient   rs17263971   SYNPO2         4    1.2E+08     0.412      **0.004**   0.412      **0.005**   0.138    0.065       0.138    0.095
  Recipient   rs7828796    --             8    84280532    0.282      **0.002**   0.282      **0.006**   0.155    **0.030**   0.155    **0.048**
  Recipient   rs13036385   BPIFB4         20   31671209    −0.306     **0.021**   −0.306     **0.031**   −0.033   0.655       −0.033   0.687
  Recipient   rs4339026    BPIFB4         20   31671599    0.306      **0.021**   0.306      **0.040**   0.204    **0.004**            \#
  Recipient   rs7643736    --             3    3767186     0.028      0.762       0.028      0.767                                     
  Recipient   rs2293925    TOP1MT         8    1.44E+08    −0.108     0.257       −0.108     0.297                                     
  Recipient   rs776746     CYP3A5         7    99672916    0.286      **0.009**   0.286      **0.005**   0.238    0.004       0.238    **0.007**
  Recipient   Age                                          −0.005     0.484       −0.005     0.543                                     
  Recipient   Gender                                       −0.135     0.456       −0.135     0.459                                     
  Donor       Gender                                       0.127      0.861       0.127      0.132                                     
  Recipient   BMI                                          −0.005     0.484       −0.005     0.552                                     
  Recipient   MELD score                                   0.011      0.349       0.011      0.265                                     
  Recipient   ALT.post                                     0.001      0.304       0.001      0.316                                     
  Recipient   TB.post                                      0.004      0.006       0.004      0.022                                     
  Recipient   Cr.post                                      5.117E-5   0.980       5.117E-5   0.972                                     
  Recipient   Hb.post                                      −0.008     0.098       −0.008     0.179                                     

BMI, body mass index; ALT.post, glutamic-pyruvic transaminase detected after transplant; TB.post, total bilirubin detected after transplant; Cr.post, creatinine detected after transplant; Hb.post, hemoglobin detected after transplant. Bold values indicate the significant level at P \< 0.05.

Analysis of Correlative SNPs and Clinical Variables in Donors and Recipients and Their Relationship With ln(TAC C~0~/D Ratio) in the CP and SP
----------------------------------------------------------------------------------------------------------------------------------------------

The association of the correlative SNPs of donors and recipients with ln(TAC C~0~/D ratio) was explored by univariate and multivariate analyses in the CP and SP. Clinical variables were simultaneously applied to the regression analysis. The significant variables, as identified by univariate analysis, were then applied to multivariate analysis. The results of the multivariate analysis revealed that there were three significant variables linked to tacrolimus metabolism in CP ([Table 2](#T2){ref-type="table"}): donor rs1927321 (*P* = 0.008, bootstrap *P* = 0.015), donor rs1057192 (*P* = 0.001, bootstrap *P* = 0.001), and preoperative creatine (*P* = 0.022, bootstrap *P* = 0.026). In SP ([Table 3](#T3){ref-type="table"}), six significant variables were identified, namely: donor rs776746 (*P* = 0.000, bootstrap *P* = 0.014), donor rs2667662 (*P* = 0.003, bootstrap *P* = 0.014), donor rs7980521 (*P* = 0.000, bootstrap *P* = 0.014), donor rs4903096 (*P* = 0.000, bootstrap *P* = 0.007), recipient rs7828796 (*P* = 0.030, bootstrap *P* = 0.048), and recipient rs776746 (*P* = 0.004, bootstrap *P* = 0.007).

Model of Variation in Tacrolimus Trough Concentration in the CP and SP
----------------------------------------------------------------------

A model was constructed by using significant SNPs and clinical variables to explain variation in tacrolimus trough concentrations in the CP and SP by linear regression respectively ([Table 4](#T4){ref-type="table"}). In CP, donor rs1927321 was responsible for 8.9% variance; donor rs1057192 was responsible for 11.1% variance, and Cr.pre was responsible for 2.9% variance. In SP, donor rs776746, donor rs2667662, donor rs7980521, donor rs4903096, recipient rs7828796, recipient rs776746 were responsible for 10.3, 8.2, 8.5, 10.3, 8.1, and 6.0% variance, respectively. Overall, the proportion of variation explained by this model was 22.0% in CP (adjusted *R*^2^ = 19.9%) and 47.8% in SP (adjusted *R*^2^ = 44.8%).

Discussion
==========

Liver transplantation is a major surgical operation, and the liver and gastrointestinal tract of post-operative recipients needs a recovery period to achieve a return to normal physiological functions. Liver function did not recover in the early period after liver transplant (CP), as at that time, the donor liver could not completely metabolize tacrolimus and the genetic function could not be observed. After the donor liver function recovered (in the SP), Tacrolimus could be metabolized completely, which indicated the donors' genetic function. During these two different periods, the genetic and clinical factors affecting tacrolimus metabolism may change. We used an exon microarray in addition to measurements of pre- and post-operative clinical indicators to explore the factors influencing tacrolimus metabolism in the different periods of recovery after liver transplantation and used this information to build appropriate models. In addition, we selected the genotype of CYP3A5, known to have a significant effect on tacrolimus metabolism, from the DMET chip. Our study identified two novel SNPs (rs1927321, rs1057192) in donors in the CP, four novel SNPs (rs776746, rs2667662, rs7980521, rs4903096) in donors in the CP, and two novel SNPs (rs7828796, rs776746) in recipients in the SP.

###### 

Tacrolimus variance in natural log--transformed dose-normalized tacrolimus troughs explained by a model in recovery phase and stabilizing phase respectively.

  Model                                                                            Tacrolimus variation explained by model, %   
  -------------------------------------------------------------------------------- -------------------------------------------- ------
  **Recovery phase**                                                                                                            
  D rs1927321                                                                      8.9                                          8.1
  D rs1057192                                                                      11.1                                         10.3
  Cr.pre                                                                           2.9                                          2.1
  Cr.pre+ D rs1927321 and D rs1057192                                              22.0                                         19.9
  **Stabilizing phase**                                                                                                         
  D rs776746                                                                       10.3                                         9.5
  D rs2667662                                                                      8.2                                          7.3
  D rs7980521                                                                      8.5                                          7.7
  D rs4903096                                                                      10.3                                         9.5
  R rs7828796                                                                      8.1                                          7.3
  R rs776746                                                                       6.0                                          5.1
  D rs776746, D rs2667662, D rs7980521, D rs4903096, R rs7828796, and R rs776746   47.8                                         44.8

D meant single nucleotide polymorphisms (SNPs) originated from a donor, R meant single nucleotide polymorphisms (SNPs) originated from the recipient; Cr.pre, creatinine detected before transplant.

The CYP3A5 genotype is a well-known factor in tacrolimus metabolism *in vitro* and *in vivo*, and is currently the most reliable predictor of an individual's tacrolimus dose requirement ([@B11]; [@B4]). As the metabolism of tacrolimus by CYP3A5 occurs mainly in the liver and intestine, CYP3A5 genotypes are relevant in both the donor liver allografts and the recipient native intestines ([@B21]). [@B10] reported that the donor CYP3A5 genotype had a minimal influence on tacrolimus metabolism in CYP3A5 non-expressor recipients during the first month, and that the effect gradually changed over time. In our study, we found that CYP3A5 polymorphisms did not correlate with variations in the tacrolimus trough concentration in either donors or recipients and was thus excluded from the model in the CP. During the SP, the association became more prominent, which indicated that the CYP3A5 polymorphism of donors and recipients did exert a short-term influence on tacrolimus metabolism in the short term, and that this influence amplified over time and may be even more remarkable in the long term.

Our findings of several novel SNPs as independent relevant factors affecting tacrolimus metabolism have not been previously described; these SNPs and their effects may provide new insights into the direction of future research. Among these SNPs, rs266762 is located in TELO2 (telomere maintenance 2), a gene involved in the maintenance of telomere length ([@B31]). The TELO2 protein can interact with phosphatidylinositol 3-kinase-related protein kinases and is a component of mTOR (mammalian target of rapamycin) ([@B9]). mTOR can protect the liver from ischemia- or reperfusion-induced injury through the NF-kB pathway. [@B32] reported that NF-kB suppressed the expression of PXR (pregnane X receptor)-mediated CYP3A5 gene. Hence, TELO2 rs26672 might affect tacrolimus pharmacokinetics through the mTOR/NF-kB/CYP3A5 pathway. ESYT1 (Extended synaptotagmin 1) rs7980521 is located on chromosome 12 with major allele G. ESYT1 is an endoplasmic reticulum protein that binds to the plasma membrane and transports lipids ([@B3]). We supposed that ESYT1 rs7980521 could affect tacrolimus metabolism through lipid transportation because tacrolimus is a fat-soluble drug. Rs1057192 is located in FAM26F (gene family with sequence similarity 26, member F), a recently identified gene reported to be involved in manifold immune responses ([@B20]). Interestingly, FAM26F has been found in several gene signatures associated with oxidative stress and inflammation in the study of liver ischemia-reperfusion injury in liver transplantation ([@B7]). In our final model, SNPs within FAM26F accounted for 11.2%, the largest share, of the tacrolimus trough variation in the CP. Therefore, FAM26F may play an intriguing role in liver transplantation and further investigation into the associated genotypes may yield meaningful results.

The influence of other covariates (such as demographics, clinical laboratory indices, disease-related factors, and cotreatments) on tacrolimus metabolism has been extensively investigated ([@B28]; [@B5]). In our study, we included some frequently reviewed covariates, including age, sex, BMI, MELD score, hematocrit, liver function (levels of AST, ALT, DB, and TB), and serum creatinine. Among all the covariates we studied, pre-operation serum creatinine concentration of recipients in the CP was the only variable that showed statistical significance. In keeping with our findings, serum creatinine was previously shown to be relevant in tacrolimus metabolism ([@B29]), whereas the other baseline characteristics we studied have been reported to have no effect. Interestingly, serum creatinine only influenced tacrolimus metabolism during CP, showing that, to a certain extent, the major factors affecting tacrolimus metabolism were genetic. The proportion of variation in metabolism explained by our model was 22.0% in the CP and 47.8% in the SP, which is, to the best of our knowledge, the highest variation reached ([@B23]). This suggested that the effects of genetic factors may be weak or may not occur in the CP, but become stronger in the SP.

There are, unfortunately, several limitations to our study. First, donor demographic data were limited. Fortunately, the quality of donor livers was strictly assessed to satisfy transplantation standards. Under these conditions, the genetic factors were critical. In addition, we did not perform functional testing of the genetic loci as the focus of this article was the identification of key SNPs for further study.

Conclusion
==========

We found that SNPs play a non-negligible role in tacrolimus metabolism, and that their role changed over time with the recovery of liver function. The novel SNPs we identified with effects on tacrolimus metabolism could deliver promising new insights into the study of the relationship between patient genotypes and tacrolimus metabolism. The two-phase models we developed based on genetic polymorphism and clinical covariates accounted for a significant portion of the inter-individual variation in tacrolimus trough concentrations and may contribute to the optimization of individual tacrolimus dosing.
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